Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company developing AL001, a lithium-based ionic cocrystal therapy, and ALZN002, a dendritic-cell vaccine, to treat Alzheimer's disease, bipolar disorder, MDD, and PTSD. It is pre-revenue and listed on NASDAQ as ALZN.
- Company typePublic
- Founded2016
- HeadquartersNewport Beach, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alzamend Neuro does
Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company founded in February 2016 by Milton C. Ault III and headquartered in Tampa, Florida, with additional offices in Newport Beach and Costa Mesa, California. The company develops two therapeutic drug candidates — both licensed under royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation — targeting Alzheimer's disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). AL001 (LiProSal) is a patented ionic cocrystal technology that delivers lithium via an engineered combination of lithium, proline, and salicylate; Phase I data demonstrated bioequivalence to marketed lithium carbonate at 50% lower dosage, and Phase II data from Massachusetts General Hospital showed superior brain delivery (reduction of myo-inositol in 17 of 18 brain regions versus 8 for lithium carbonate) with a benign safety profile. ALZN002 is a cell-based therapeutic vaccine that uses autologous dendritic cells pulsed with a mutant amyloid-beta peptide (E22W) to stimulate the patient's immune system against beta-amyloid, with FDA clearance for a Phase I/IIA trial secured in October 2022.
The company has 1–10 employees, completed its NASDAQ IPO in June 2021 raising $14.4 million in gross proceeds, and has subsequently raised additional capital through milestone-based investments from Ault Alliance–affiliated Digital Power Lending LLC ($10M committed, $8M funded), a $25M registered direct offering facility (May 2024), and a $5M private placement (June 2025). Revenue model is pre-commercial: no product sales, no licensing royalties, and no recurring revenue. Commercialization is contingent on FDA approval, after which the company plans to use standard pharmaceutical wholesale and pharmacy distribution channels. The company is governed by an insider-heavy board and management team with significant overlap to Ault Alliance, its largest related-party investor.
Alzamend Neuro firmographics
Firmographics- Name
- Alzamend Neuro
- Legal name
- Alzamend Neuro, Inc.
- Website
- https://alzamend.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Alzamend Neuro is a clinical-stage biopharmaceutical company developing AL001, a lithium-based ionic cocrystal therapy, and ALZN002, a dendritic-cell vaccine, to treat Alzheimer's disease, bipolar disorder, MDD, and PTSD. It is pre-revenue and listed on NASDAQ as ALZN.
- Ownership category
- akta.pro rank
Alzamend Neuro industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals — Alzheimer's and CNS therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Dendritic Cell & Other APC-based Therapies (HLAAABAF)
Keywords
Where Alzamend Neuro is headquartered
LocationHeadquarters
- HQ city
- Newport Beach
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Alzamend Neuro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue model will be based on sales of approved drug products (AL001 and ALZN002) through traditional pharmaceutical distribution channels upon successful FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Alzamend Neuro product offering
Product offeringCore offering
Alzamend Neuro is a clinical-stage biopharmaceutical company developing two therapeutic drug candidates: AL001 (LiProSal), a patented ionic cocrystal delivering lithium via a combination of lithium, proline, and salicylate for Alzheimer's, bipolar disorder, MDD, and PTSD; and ALZN002, a mutant-peptide sensitized autologous dendritic cell-based therapeutic vaccine for Alzheimer's disease. Both candidates are licensed from the University of South Florida Research Foundation under royalty-bearing exclusive worldwide licenses and are advancing through FDA-regulated clinical trials.
Product overview
Alzamend Neuro is a clinical-stage biopharmaceutical company developing two novel therapeutic drug candidates: AL001 (LiProSal) is a lithium-based ionic cocrystal oral therapy for treating Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD; ALZN002 is an autologous dendritic cell-based therapeutic vaccine targeting amyloid-beta proteins to treat Alzheimer's disease. Both product candidates are licensed from the University of South Florida Research Foundation pursuant to royalty-bearing exclusive worldwide licenses.
Differentiator
Problem solved
Functional benefit
Products and services
- AL001 (LiProSal) A patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate. Under development as an oral treatment for patients with dementia related to Alzheimer's disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Demonstrated bioequivalence to standard lithium carbonate with potentially superior brain delivery and fewer side effects.
- ALZN002 A patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease. Consists of autologous dendritic cells pulsed with a novel amyloid-beta peptide (E22W) to stimulate the immune system to reduce beta-amyloid protein burden in the brain.
Quantifiable outcome
- AL001 at 150mg dosage demonstrated bioequivalence to 300mg lithium carbonate in Phase I trial
- +2 more outcomes
Companies that use Alzamend Neuro
Customer profileSegments4 records
Ideal customer profiles2 records
Alzamend Neuro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alzamend Neuro partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- BiorasicoreContract research organization (CRO) partnered to conduct the first-in-human, randomized, double-blind, placebo-controlled, parallel group Phase I/IIA clinical trial for ALZN002.
- Miller School of Medicine, Interdisciplinary Stem Cell Institute at University of MiamicorePartnership for Phase I/IIA clinical trial of ALZN002 immunotherapy vaccine to treat mild to moderate dementia of the Alzheimer's type. The institute manufactures the patient-specific vaccine using autologous dendritic cells.
- AltasciencessupportingContracted to manage and conduct Phase IIA study in patients with Alzheimer's disease. Previously contracted for Phase I relative bioavailability study.
- iResearch AtlantasupportingContracted alongside Altasciences to manage and conduct the Phase IIA study in patients with Alzheimer's.
- University of South Florida Research Foundation, Inc.coreBoth product candidates (AL001 and ALZN002) are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. Dr. Cao's research team at USF Health Byrd Alzheimer's Institute was foundational to the company's technology development.
- Massachusetts General HospitalcorePhase II clinical trials for AL001 conducted at Massachusetts General Hospital using advanced MRI/MRS neuroimaging to assess lithium pharmacokinetics in blood and brain tissue. The hospital serves as the primary clinical trial site for the 'Lithium in Brain' study.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Alzamend Neuro competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Alzamend Neuro social profiles
Digital presenceAlzamend Neuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alzamend Neuro leadership team
Management profileNumber of profiles
Profiles13 records
Alzamend Neuro funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alzamend Neuro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alzamend Neuro
What does Alzamend Neuro do?
Alzamend Neuro is a clinical-stage biopharmaceutical company developing two therapeutic drug candidates: AL001 (LiProSal), a patented ionic cocrystal delivering lithium via a combination of lithium, proline, and salicylate for Alzheimer's, bipolar disorder, MDD, and PTSD; and ALZN002, a mutant-peptide sensitized autologous dendritic cell-based therapeutic vaccine for Alzheimer's disease. Both candidates are licensed from the University of South Florida Research Foundation under royalty-bearing exclusive worldwide licenses and are advancing through FDA-regulated clinical trials.
Is Alzamend Neuro a public or private company?
Alzamend Neuro is a public company. It is classified as public and is currently operating.
When was Alzamend Neuro founded?
Alzamend Neuro was founded in 2016. It employs 1 to 10 people.
Where is Alzamend Neuro based?
Alzamend Neuro is headquartered in Newport Beach, United States, in the North America region.
How does Alzamend Neuro make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Alzamend Neuro have an API?
No public API is recorded for Alzamend Neuro.
What industry is Alzamend Neuro in?
Alzamend Neuro's product category is Clinical-stage biopharmaceuticals — Alzheimer's and CNS therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.